Published in N Engl J Med on December 20, 2012
Targeting interleukin-1 in heart disease. Circulation (2013) 2.52
Treating inflammation by blocking interleukin-1 in humans. Semin Immunol (2013) 1.75
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 1.51
Inflammasomes in the CNS. Nat Rev Neurosci (2014) 1.44
IL-1 blockade in autoinflammatory syndromes. Annu Rev Med (2014) 1.10
Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et Al. Arthritis Rheumatol (2015) 1.07
Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol (2014) 1.06
Treatment of adult-onset Still's disease: a review. Ther Clin Risk Manag (2014) 1.04
Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol (2015) 0.96
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis (2015) 0.94
Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J (2014) 0.93
Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol (2014) 0.91
Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep (2014) 0.90
The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol (2015) 0.90
The development and assessment of biological treatments for children. Br J Clin Pharmacol (2015) 0.89
Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther (2015) 0.87
From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol (2015) 0.87
Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J (2016) 0.87
2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken) (2013) 0.86
A new era in the treatment of systemic juvenile idiopathic arthritis. N Engl J Med (2012) 0.85
Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J (2013) 0.85
Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol Ther Methods Clin Dev (2014) 0.84
Evasion of inflammasome activation by microbial pathogens. J Clin Invest (2015) 0.84
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol (2016) 0.84
An expanding role for interleukin-1 blockade from gout to cancer. Mol Med (2014) 0.82
Neutralizing anti-interleukin-1β antibodies modulate fetal blood-brain barrier function after ischemia. Neurobiol Dis (2014) 0.82
Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. Clin Epidemiol (2014) 0.82
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol (2013) 0.81
Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? Arthritis Res Ther (2016) 0.81
IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. PLoS One (2014) 0.80
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis (2016) 0.80
The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs (2015) 0.79
Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol (2016) 0.79
Treatment in juvenile rheumatoid arthritis and new treatment options. Turk Pediatri Ars (2015) 0.79
Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis (2015) 0.79
Advances in the genetically complex autoinflammatory diseases. Semin Immunopathol (2015) 0.79
Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside. Pediatr Rheumatol Online J (2014) 0.79
Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol (2015) 0.79
What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther (2013) 0.79
Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years. Rheumatol Int (2014) 0.78
Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatol Ther (2016) 0.78
Therapeutic Potential of Interferon-γ and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Pharmaceuticals (Basel) (2015) 0.78
Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int (2016) 0.78
Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. Rheumatology (Oxford) (2016) 0.78
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open (2016) 0.78
Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis (2016) 0.77
Update on the treatment of juvenile idiopathic arthritis. Curr Allergy Asthma Rep (2013) 0.77
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open (2015) 0.77
Targeting the inflammasome in rheumatic diseases. Transl Res (2015) 0.77
Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J (2015) 0.77
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. Front Pharmacol (2016) 0.77
Indications for IVIG in rheumatic diseases. Rheumatology (Oxford) (2014) 0.77
Found in Translation: International initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki Disease. Arthritis Rheumatol (2016) 0.77
Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes. Curr Opin Rheumatol (2014) 0.77
[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics]. Z Rheumatol (2014) 0.76
[Regulation of proinflammatory and anti-inflammatory Th17 cells]. Z Rheumatol (2013) 0.76
The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review. Cardiol Res Pract (2016) 0.76
Paediatric rheumatology: Biologic therapy for systemic juvenile idiopathic arthritis--times they are a'changing! Nat Rev Rheumatol (2013) 0.76
Regulating against the dysregulation: new treatment options in autoinflammation. Semin Immunopathol (2015) 0.76
Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol (2016) 0.76
Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol (2013) 0.76
Adult-onset Still's disease: current challenges and future prospects. Open Access Rheumatol (2016) 0.75
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol (2015) 0.75
Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Rheumatol Int (2014) 0.75
Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management. Front Immunol (2017) 0.75
Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J Ophthalmol (2016) 0.75
Infection-Related Death among Persons with Refractory Juvenile Idiopathic Arthritis. Emerg Infect Dis (2016) 0.75
Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Pediatr Rheumatol Online J (2015) 0.75
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther (2017) 0.75
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J (2017) 0.75
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther (2016) 0.75
Treatment of systemic-onset juvenile arthritis with canakinumab. Open Access Rheumatol (2015) 0.75
Pediatric Acute Liver Failure of Undetermined Cause: A Research Workshop. Hepatology (2016) 0.75
Juvenile Idiopathic Arthritis in the Era of International Cooperation. Rambam Maimonides Med J (2017) 0.75
Juvenile Idiopathic Arthritis. Balkan Med J (2017) 0.75
Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J (2017) 0.75
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. Front Pharmacol (2017) 0.75
New frontiers in the treatment of systemic juvenile idiopathic arthritis. F1000Res (2017) 0.75
The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. Front Med (Lausanne) (2017) 0.75
Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol (2016) 0.75
Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis. Curr Treatm Opt Rheumatol (2017) 0.75
Biologics in juvenile idiopathic arthritis: a narrative review. Eur J Pediatr (2017) 0.75
Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review. Clin Rheumatol (2015) 0.75
[Biologics]. Z Rheumatol (2016) 0.75
Rheumatologic emergencies. Clin Rheumatol (2015) 0.75
Successful remission induced by plasma exchange combined with leukocytapheresis against refractory systemic juvenile idiopathic arthritis. Eur J Pediatr (2013) 0.75
Clinical Trial Design in Juvenile Idiopathic Arthritis. Paediatr Drugs (2017) 0.75
Co-occurrence of Kikuchi-Fujimoto's disease and Still's disease: case report and review of previously reported cases. Clin Rheumatol (2014) 0.75
Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A (2009) 15.09
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Juvenile idiopathic arthritis. Lancet (2007) 5.64
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet (2002) 4.84
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med (2014) 4.70
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 4.15
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum (2007) 3.65
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis (2010) 3.47
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2007) 3.32
Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med (2005) 3.29
Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med (2007) 3.18
Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) (2005) 3.01
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum (2007) 2.56
Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum (2007) 2.56
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum (2005) 2.55
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol (2011) 2.55
Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum (2005) 2.48
Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum (2009) 2.48
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci U S A (2010) 2.43
Juvenile idiopathic arthritis. Lancet (2011) 2.40
Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol (2012) 2.38
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum (2006) 2.27
Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum (2011) 2.24
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2012) 2.21
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2003) 2.20
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) (2003) 2.18
Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol (2010) 2.17
Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis (2013) 2.09
Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet (2003) 2.08
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2008) 2.08
Pregnancy outcome in juvenile systemic lupus erythematosus: a Brazilian multicenter cohort study. J Rheumatol (2008) 2.04
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA (2010) 2.02
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet (2011) 1.97
Access to biologic therapies in Canada for children with juvenile idiopathic arthritis. J Rheumatol (2012) 1.97
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol (2012) 1.93
Effect of honey on nocturnal cough and sleep quality: a double-blind, randomized, placebo-controlled study. Pediatrics (2012) 1.92
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics (2003) 1.91
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr (2005) 1.91
Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol (2003) 1.90
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood (2011) 1.89
Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med (2003) 1.89
Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum (2009) 1.89
Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell (2004) 1.85
The publication rate of abstracts from the 4th Park City Pediatric Rheumatology meeting in peer-reviewed journals: what factors influenced publication? J Rheumatol (2003) 1.84
Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet (2011) 1.84